TiumBio
VerifiedA drug developer working on treatments for cancer based in South Korean.
Launch date
Employees
Market cap
KRW151.2b
Net debt
KRW1.5b
Enterprise valuation
$125m (Public information from Jun 2024)
Share price
KRW5490 321550.KQ
Seongnam-si Gyeonggi-do (HQ)
Deals in current and previous year:
| KRW | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (6 %) | (95 %) | 15896 % | (46 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (646 %) | (1171 %) | (53953 %) | (243 %) | (247 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (637 %) | (1155 %) | (55504 %) | (327 %) | (366 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 937 % | 45266 % | 233 % | 365 % |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | $0.0 | round |
| investor investor | $0.0 | round | |
| investor investor investor investor investor investor investor investor | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
* | N/A | $12.0m | Post IPO Equity |
| Total Funding | 000k | ||
Related Content
Recent News about TiumBio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
